Ipamorelin and CJC-1295 are both classified as growth hormone secretagogues — compounds that stimulate the pituitary gland to release its own growth hormone (GH), rather than supplying exogenous GH directly.
Although frequently discussed together, the two compounds act on entirely different receptors and represent two distinct branches of GH-axis research.
Two Different Receptor Pathways
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH). It acts on the GHRH receptor on pituitary somatotroph cells, stimulating cAMP-dependent GH synthesis and release.
Ipamorelin belongs to a structurally distinct class — it is a selective agonist at the ghrelin receptor (GHS-R1a), triggering a calcium-dependent signalling cascade that leads to GH granule release. Research has characterised Ipamorelin as notably selective: compared to earlier growth hormone-releasing peptides, it has been reported to stimulate GH release with substantially less effect on cortisol and prolactin.
Documented Research Areas
Pulsatile GH Release Patterns
CJC-1295 is most often studied in a modified form incorporating a Drug Affinity Complex (DAC), which extends its half-life considerably, producing a sustained elevation in baseline GH and IGF-1 over several days. A version without this modification has a much shorter half-life and has been studied for its closer alignment with the timed, pulsatile character of natural GHRH signalling.
Ipamorelin, by contrast, has a considerably shorter half-life and is associated with producing a single, time-limited GH pulse following administration.
Receptor Synergy Research
Because CJC-1295 and Ipamorelin act on two separate receptor systems, research has examined what happens when both pathways are activated simultaneously. Published research has reported that combined GHRH and GHRP receptor stimulation produces a GH response significantly greater than the sum of either pathway activated alone.
Selectivity and Off-Target Hormone Effects
A specific research focus for Ipamorelin has been its comparative selectivity profile. Older-generation GHRPs are associated with meaningful co-stimulation of cortisol, prolactin, and appetite alongside GH release. Ipamorelin’s research profile is distinguished by a reported reduction in these off-target effects.
What the Research Does Not Establish
The majority of mechanistic literature for both compounds derives from in vitro and animal-model research, alongside a body of human pharmacodynamic studies focused specifically on GH and IGF-1 response measurements. Long-term human data on either compound over extended research periods remains limited.
Sourcing Research-Grade Ipamorelin and CJC-1295
Any Ipamorelin or CJC-1295 used in a laboratory setting should be accompanied by a batch-specific Certificate of Analysis confirming identity, purity, and screening for heavy metals and endotoxins. At Claripep, every batch of both compounds is independently tested by a third-party laboratory before listing.
This article is provided for research and educational purposes only and does not constitute medical advice. All products supplied by Claripep Ltd are intended strictly for laboratory research applications.